The promise and challenge of new biological treatments for psoriasis: how do they impact quality of life?

Dermatologic Therapy
S R Rapp, Steven R Feldman

Abstract

Psoriasis disrupts a patient's work, play, and relationships and impacts how patients view themselves. These effects are measured through the concept of quality of life. The most central feature of the concept of HRQL (health-related quality of life) is that it represents the patient's perspective, helping understand the full impact of the illness on patients' lives. Psoriasis causes a high level of physical impairment, social impairment, emotional distress, occupational interference, and disruptions in leisure activities. HRQL can be measured with a variety of instruments that are acceptable to patients and have demonstrated adequate psychometric properties (e.g., reliability, validity, and sensitivity to change). These include global, skin-specific, and psoriasis-specific measures. Although generic measures are useful in comparing the impact of psoriasis to that of other diseases, skin-specific and psoriasis-specific measures are more sensitive to the impact of the disease and are useful in demonstrating the impact of treatment on the lives of patients with psoriasis. These measures have been used to show the benefits new biologic medications offer our patients.

References

Jan 1, 1978·Dermatologica·T Fredriksson, U Pettersson
Jan 1, 1976·Medical Care·M BergnerB S Gilson
Jan 1, 1976·International Journal of Health Services : Planning, Administration, Evaluation·M BergnerJ R Morris
Dec 1, 1975·American Journal of Public Health·B S GilsonM Vesselago
Feb 1, 1976·Medical Care·W E PollardB S Gilson
Dec 1, 1990·The British Journal of Dermatology·A Y FinlayM S Salek
Jan 1, 1987·Clinical and Experimental Dermatology·A Y Finlay, S E Kelly
May 1, 1981·Social Science & Medicine. Part A, Medical Sociology·S M HuntE Papp
Jun 1, 1994·The Journal of Investigative Dermatology·A B FleischerS R Feldman
May 1, 1994·Clinical and Experimental Dermatology·A Y Finlay, G K Khan
Nov 1, 1996·The Journal of Investigative Dermatology·M M ChrenS J Zyzanski
Dec 16, 1998·Health Psychology : Official Journal of the Division of Health Psychology, American Psychological Association·M R LearyS R Feldman
Mar 13, 1999·Social Science & Medicine·S M SkevingtonS Saxena
Aug 25, 1999·Journal of the American Academy of Dermatology·S R RappD M Reboussin
May 22, 2001·The British Journal of Dermatology·C R TouwA Y Finlay
Nov 13, 2001·The British Journal of Dermatology·S R RappM R Leary
Feb 9, 2002·Dermatology : International Journal for Clinical and Investigative Dermatology·Damiano AbeniMary Margaret Chren
Jan 30, 2003·American Journal of Clinical Dermatology·Charles N EllisUNKNOWN Randomized, placebo-controlled phase II trial
May 29, 2003·Dermatology : International Journal for Clinical and Investigative Dermatology·A Y FinlayUNKNOWN Alefacept Clinical Study Group
Jun 6, 2003·Journal of the American Academy of Dermatology·Alice B GottliebDaniel G Baker
Sep 19, 2003·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·Upasana NandaEric Armbrecht
Nov 14, 2003·Health and Quality of Life Outcomes·Richard ShikiarDennis A Revicki
Nov 25, 2003·The New England Journal of Medicine·Craig L LeonardiUNKNOWN Etanercept Psoriasis Study Group
Dec 18, 2003·JAMA : the Journal of the American Medical Association·Kenneth B GordonUNKNOWN Efalizumab Study Group
Oct 1, 1997·Journal of Health Psychology·S R RappA Clark

❮ Previous
Next ❯

Citations

Jan 1, 2009·Clinical, Cosmetic and Investigational Dermatology·Rosita SaracenoSergio Chimenti
May 16, 2007·The Journal of Investigative Dermatology. Symposium Proceedings·Jennifer K TanAlice B Gottlieb
Aug 30, 2008·Clinics in Dermatology·Marc Alexander Radtke, Matthias Augustin
May 28, 2009·Journal of the European Academy of Dermatology and Venereology : JEADV·I GardinalC Paul
Feb 21, 2006·Journal of the American Academy of Dermatology·Rosita Saraceno, Christopher E M Griffiths
Dec 1, 2007·Expert Review of Pharmacoeconomics & Outcomes Research·Noah Scheinfeld, Daniel Parish
May 20, 2005·Seminars in Cutaneous Medicine and Surgery·Kevin R SteinSteven R Feldman

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of the American Academy of Dermatology
S R RappD M Reboussin
The Journal of Investigative Dermatology. Symposium Proceedings
John de KorteJan D Bos
The New England Journal of Medicine
C N EllisAlefacept Clinical Study Group
International Journal of Dermatology
M A GuptaC N Ellis
© 2021 Meta ULC. All rights reserved